PMB IM/IV/ Intrathecal Injection
Polymyxin B
5,00,000 Units per vial
Square Pharmaceuticals Ltd.
| Pack size | 1’s Pack |
|---|---|
| Unite Price | 400.00 BDT |
Indications
PMB IM/IV/ Intrathecal Injection is used for:
Susceptible infections, Meningitis
Adult Dose
Intravenous
Susceptible infections
Adult: 15,000-25,000 U/kg daily by continuous IV drip or intermittent infusion 12 hrly at 60-120 min duration. Max: 2,000,000 U/day.
Intramuscular
Susceptible infections
Adult: 25,000-30,000 U/kg daily in divided doses 4-6 hrly. Max: 2,000,000 U/day.
Intrathecal
Meningitis
Adult: 50,000 U once daily for 3-4 days, then on alternate days for at least 2 wk after CSF cultures are negative and CSF glucose content is normal. Max: 2,000,000 U/day.
Child Dose
Intravenous
Susceptible infections
Adult: 15,000-25,000 U/kg daily by continuous IV drip or intermittent infusion 12 hrly at 60-120 min duration. Max: 2,000,000 U/day.
Child: <2 yr 40,000 U/kg daily in divided doses 12 hrly; ?2 yr Same as adult dose.
Intramuscular
Susceptible infections
Child: <2 yr 40,000 U/kg daily in divided doses 6 hrly (not routinely recommended due to pain at injection sites);
>2 yr Same as adult dose but not routinely recommended due to pain at injection sites.
Intrathecal
Meningitis
Child: <2 yr 20,000 U once daily for 3-4 days or 25,000 U on alternate days, followed by the latter dose for at least 2 wk after CSF cultures are negative and CSF glucose content is normal;
>2 yr Same as adult dose.
Renal Dose
Renal Impairment
CrCl >20 mL/minute: give 75-100% usual dose/day divided q12hr
CrCl 5-20 mL/minute: give 50% usual dose/day divided q12hr
CrCl <5 mL/minute: give 15% usual dose/day q12hr
Administration
IV/IM/IT Preparation
IV: dilute 500,000 U in 300-500 mL D5W
IM: reconstitute vial with 2 mL SWI , NS, or procaine HCl 1% solution
Intrathecal (IT): reconstitute vial with10 mL NS; DO NOT use procaine HCl for IT
IV/IM Administration
IV: infuse over 60-90 min
IM: give deep into upper outer quadrant of gluteal muscles
Contra Indications
Hypersensitivity to polymyxins; Concurrent use w/ nephrotoxic and/or neurotoxic drugs and neuromuscular blockers.
Precautions
Oliguria, myasthenia gravis, pregnancy, renal disease
Potential risk of nephrotoxicity and neurotoxicity
May inhibit neuromuscular transmission
Inactivated by strong acidic or alkaline solution
Discontinue if diminished urine output, rise in SCr or BUN, or signs of respiratory paralysis appear
Do not use IM routinely, particularly in peds, because of severe inj site pain
Pregnancy-Lactation
Pregnancy Category: B: use when benefits outweigh risks
Lactation: use caution; no data
Interactions
Potentially Fatal: Additive neurotoxic or nephrotoxic effect w/ bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, colistin. Increased risk of resp paralysis w/ neuromuscular blockers (e.g. anaesthetics, muscle relaxants).
Side Effects
Side effects of Polymyxin B :
Frequency Not Defined
Anaphylactoid reactions with dyspnea and tachycardia
Eosinophilia
Fever
Nephrotoxicity
Neurotoxicity
Skin exanthemata
Urticaria
Mode of Action
Polymyxin B binds to phospholipids, alters permeability and disrupts the bacterial cytoplasmic membrane of mostly gm-ve organisms allowing leakage of intracellular constituents by binding to membrane phospholipids.
Note
PMB 5,00,000 Units per vial IM/IV/ Intrathecal Injection generic name is Polymyxin B. PMB 5,00,000 Units per vial IM/IV/ Intrathecal Injection is manufactured by Square Pharmaceuticals Ltd.PMB is availble in all over Bangladesh.
Mes BD drug index information on PMB IM/IV/ Intrathecal Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.